StockNews.com upgraded shares of Fulgent Genetics (NASDAQ:FLGT – Free Report) from a sell rating to a hold rating in a research report released on Wednesday. Separately, Piper Sandler decreased their ...

Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.

Proficio Capital Partners LLC bought a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Fulgent Genetics (FLGT) to $16 from $22 following quarterly results.

Q4 2024 Earnings Call Transcript February 28, 2025 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

UBS analyst Dan Leonard lowered the firm’s price target on Fulgent Genetics (FLGT) to $20 from $27 and keeps a Neutral rating on the shares.

Laboratory services and therapeutic development specialist Fulgent Genetics (NASDAQ:FLGT) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday ...

Full Year 2024 Results Key Financial Results Revenue: US$283.5m (down 2.0% from ...

Fulgent Genetics reported a significant earnings beat for Q4 2024, posting an EPS of $0.04 against a forecasted loss of $0.39. Despite this positive surprise, the stock fell 1.85% in pre-market ...

Please go ahead. Thanks, Kevin. Good morning, and welcome to the Fulgent's fourth-quarter and full-year 2024 financial results conference call. On the call today are Ming Hsieh, Chief Executive ...

Fulgent Genetics specializes in laboratory services and therapeutic development. Its laboratory division provides anatomic pathology and precision diagnostic testing through certified laboratories ...